{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:35:34Z","timestamp":1793957734221,"version":"4.8.0"},"reference-count":54,"publisher":"BMJ","issue":"7421","license":[{"start":{"date-parts":[[2003,10,23]],"date-time":"2003-10-23T00:00:00Z","timestamp":1066867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2003,7,15]]},"published-print":{"date-parts":[[2003,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    To review outcomes in randomised controlled trials comparing hydralazine against other antihypertensives for severe hypertension in pregnancy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Study design<\/jats:bold>\n                    Meta-analysis of randomised controlled trials (published between 1966 and September 2002) of short acting antihypertensives for severe hypertension in pregnancy. Independent data abstraction by two reviewers. Data were entered into RevMan software for analysis (fixed effects model, relative risk and 95% confidence interval); in a secondary analysis, risk difference was also calculated.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    Of 21 trials (893 women), eight compared hydralazine with nifedipine and five with labetalol. Hydralazine was associated with a trend towards less persistent severe hypertension than labetalol (relative risk 0.29 (95% confidence interval 0.08 to 1.04); two trials), but more severe hypertension than nifedipine or isradipine (1.41 (0.95 to 2.09); four trials); there was significant heterogeneity in outcome between trials and differences in methodological quality. Hydralazine was associated with more maternal hypotension (3.29 (1.50 to 7.23); 13 trials); more caesarean sections (1.30 (1.08 to 1.59); 14 trials); more placental abruption (4.17 (1.19 to 14.28); five trials); more maternal oliguria (4.00 (1.22 to 12.50); three trials); more adverse effects on fetal heart rate (2.04 (1.32 to 3.16); 12 trials); and more low Apgar scores at one minute (2.70 (1.27 to 5.88); three trials). For all but Apgar scores, analysis by risk difference showed heterogeneity between trials. Hydralazine was associated with more maternal side effects (1.50 (1.16 to 1.94); 12 trials) and with less neonatal bradycardia than labetalol (risk difference -0.24 (-0.42 to -0.06); three trials).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    The results are not robust enough to guide clinical practice, but they do not support use of hydralazine as first line for treatment of severe hypertension in pregnancy. Adequately powered clinical trials are needed, with a comparison of labetalol and nifedipine showing the most promise.\n                  <\/jats:p>","DOI":"10.1136\/bmj.327.7421.955","type":"journal-article","created":{"date-parts":[[2003,10,23]],"date-time":"2003-10-23T23:06:48Z","timestamp":1066950408000},"page":"955","source":"Crossref","is-referenced-by-count":339,"title":["Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis"],"prefix":"10.1136","volume":"327","author":[{"given":"Laura A","family":"Magee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Cham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J","family":"Waterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Ohlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"von Dadelszen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2003,10,23]]},"reference":[{"key":"2025122509325251000_327.7421.955.1","first-page":"1245","article-title":"Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy.","volume":"157","author":"Rey","year":"1997","journal-title":"CMAJ"},{"key":"2025122509325251000_327.7421.955.2","unstructured":"Department of Health . Report on confidential enquiries into maternal deaths in England and Wales 1982\u00e2\u0080\u00931984. London: HMSO, 1989."},{"key":"2025122509325251000_327.7421.955.3","unstructured":"Department of Health . Report on confidential enquiries into maternal deaths in the United Kingdom 1985\u00e2\u0080\u00931987. London: HMSO, 1991."},{"key":"2025122509325251000_327.7421.955.4","unstructured":"Department of Health . Report on confidential enquiries into maternal deaths in the United Kingdom 1988\u00e2\u0080\u00931990. London: HMSO, 1994."},{"key":"2025122509325251000_327.7421.955.5","unstructured":"Department of Health . Report on confidential enquiries into maternal deaths in the United Kingdom 1991\u00e2\u0080\u00931993. London: HMSO, 1996."},{"key":"2025122509325251000_327.7421.955.6","unstructured":"Lewis G Drife J eds. Why mothers die 1997\u00e2\u0080\u00931999. The confidential enquiries into maternal deaths in the UK. London: RCOG Press, 2001."},{"key":"2025122509325251000_327.7421.955.7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0002-9378(00)99785-0","volume":"183","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"2025122509325251000_327.7421.955.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828X.2000.tb01136.x"},{"key":"2025122509325251000_327.7421.955.9","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1471-0528.1993.tb15120.x","article-title":"Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks.","volume":"100","author":"Impey","year":"1993","journal-title":"Br J Obstet Gynaecol"},{"key":"2025122509325251000_327.7421.955.10","doi-asserted-by":"publisher","DOI":"10.3109\/00016349209007974"},{"key":"2025122509325251000_327.7421.955.11","first-page":"519","article-title":"Effect of dihydralazine on the fetus in the treatment of maternal hypertension.","volume":"55","author":"Vink","year":"1980","journal-title":"Obstet Gynecol"},{"key":"2025122509325251000_327.7421.955.12","first-page":"475","article-title":"The effect of low-dose dihydrallazine on the fetus in the emergency treatment of hypertension in pregnancy.","volume":"62","author":"Vink","year":"1982","journal-title":"S Afr Med J"},{"key":"2025122509325251000_327.7421.955.13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0002-9378(88)80072-3","article-title":"Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia?","volume":"159","author":"Waisman","year":"1988","journal-title":"Am J Obstet Gynecol"},{"key":"2025122509325251000_327.7421.955.14","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/bmj.318.7194.1332","article-title":"Fortnightly review: management of hypertension in pregnancy.","volume":"318","author":"Magee","year":"1999","journal-title":"BMJ"},{"key":"2025122509325251000_327.7421.955.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803053381009"},{"key":"2025122509325251000_327.7421.955.16","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199816120-00016"},{"key":"2025122509325251000_327.7421.955.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)05381-6"},{"key":"2025122509325251000_327.7421.955.18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1471-0528.1994.tb13126.x","article-title":"The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade.","volume":"101","author":"Ben Ami","year":"1994","journal-title":"Br J Obstet Gynaecol"},{"key":"2025122509325251000_327.7421.955.19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0002-9378(89)90226-3","article-title":"Neuromuscular blockade with magnesium-sulfate and nifedipine.","volume":"161","author":"Snyder","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"2025122509325251000_327.7421.955.20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.5694\/j.1326-5377.1997.tb123300.x","article-title":"Withdrawal of nifedipine capsules: jeopardizing the treatment of acute severe hypertension in pregnancy? Australasian Society for the Study of Hypertension in Pregnancy.","volume":"166","author":"Brown","year":"1997","journal-title":"Med J Aust"},{"key":"2025122509325251000_327.7421.955.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70277-6"},{"key":"2025122509325251000_327.7421.955.22","doi-asserted-by":"crossref","unstructured":"Egger M Smith GD . Principles of and procedures for systematic reviews. Egger M Smith GD Altman DG eds. Systematic reviews in health care: meta-analysis in context. London: BMJ Books, 2003: 23\u00e2\u0080\u009342.","DOI":"10.1002\/9780470693926.ch2"},{"key":"2025122509325251000_327.7421.955.23","unstructured":"Clarke M Oxman AD eds. Cochrane reviewer's handbook 4.2.0. In: Cochrane Library, Issue 2, 2003. http:\/\/www.cochrane.de\/cochrane\/hbook.htm (accessed 24 Sep 2003)."},{"key":"2025122509325251000_327.7421.955.24","unstructured":"Organization of a systematic review for the Cochrane Neonatal Review Group: guidelines for reviewers and editors . Cochrane Collaboration, 2002. http:\/\/hiru.mcmaster.ca\/cochrane\/centres\/canadian\/neonatal\/checklist.pdf (accessed 16 Sep 2003)."},{"key":"2025122509325251000_327.7421.955.25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1471-0528.1998.tb10202.x","article-title":"The haemodynamic effects of ketanserin versus dihydralazine in severe early-onset hypertension in pregnancy.","volume":"105","author":"Bolte","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"2025122509325251000_327.7421.955.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(99)70216-4"},{"key":"2025122509325251000_327.7421.955.27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1471-0528.1991.tb10339.x","article-title":"Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol.","volume":"98","author":"Harper","year":"1991","journal-title":"Br J Obstet Gynaecol"},{"key":"2025122509325251000_327.7421.955.28","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(95)02372-J"},{"issue":"suppl","key":"2025122509325251000_327.7421.955.29","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.1093\/ajh\/7.7.61S","article-title":"Intravenous isradipine in the management of severe hypertension in pregnant and nonpregnant patients. A pilot study.","volume":"7","author":"Maharaj","year":"1994","journal-title":"Am J Hypertens"},{"key":"2025122509325251000_327.7421.955.30","first-page":"54","article-title":"Intravenous isradipine in the management of severe hypertension of pregnancy in black patients: a pilot study.","volume":"1","author":"Maharaj","year":"1994","journal-title":"Blood Press Suppl"},{"key":"2025122509325251000_327.7421.955.31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10641959709069085","article-title":"A comparative study of intravenous isradipine and dihydralazine in the treatment of severe hypertension of pregnancy in black patients.","volume":"16","author":"Maharaj","year":"1997","journal-title":"Hypertens Pregn"},{"key":"2025122509325251000_327.7421.955.32","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1471-0528.1992.tb13872.x","article-title":"A comparative study of the use of epoprostenol and dihydralazine in severe hypertension in pregnancy.","volume":"99","author":"Moodley","year":"1992","journal-title":"Br J Obstet Gynaecol"},{"key":"2025122509325251000_327.7421.955.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(97)00123-1"},{"key":"2025122509325251000_327.7421.955.34","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(93)90123-E"},{"key":"2025122509325251000_327.7421.955.35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/oxfordjournals.ndt.a027825","article-title":"Treatment of hypertension in patients with pre-eclampsia: a prospective parallel-group study comparing dihydralazine with urapidil.","volume":"13","author":"Wacker","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"2025122509325251000_327.7421.955.36","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0412.2002.810105.x"},{"key":"2025122509325251000_327.7421.955.37","unstructured":"Bolte AC van Geijn HP Bekedam DJ Dekker GA . Ketanserin, a serotonin2 receptor blocker, for hypertension in pregnancy [abstract]. Hypertens Pregn 2002; 9."},{"key":"2025122509325251000_327.7421.955.38","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-18226"},{"key":"2025122509325251000_327.7421.955.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828X.1992.tb02846.x"},{"key":"2025122509325251000_327.7421.955.40","first-page":"76","article-title":"Manejo de la preeclampsia severa\/eclampsia. Comparacion entre nifedipina e hidralazina como medicamentos antihipertensivos.","volume":"61","author":"Rodriguez","year":"1993","journal-title":"Ginec Obst Mex"},{"key":"2025122509325251000_327.7421.955.41","first-page":"354","article-title":"Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy.","volume":"71","author":"Ashe","year":"1987","journal-title":"S Afr Med J"},{"key":"2025122509325251000_327.7421.955.42","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/0002-9378(93)90383-T","article-title":"Malignant ventricular arrhythmias in eclampsia: a comparison of labetalol with dihydralazine.","volume":"168","author":"Bhorat","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"2025122509325251000_327.7421.955.43","first-page":"331","article-title":"Nifedipine in the treatment of severe preeclampsia.","volume":"77","author":"Fenakel","year":"1991","journal-title":"Obstet Gynecol"},{"key":"2025122509325251000_327.7421.955.44","first-page":"371","article-title":"Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy.","volume":"1","author":"Garden","year":"1982","journal-title":"Clin Exp Hypertens B"},{"key":"2025122509325251000_327.7421.955.45","doi-asserted-by":"publisher","DOI":"10.3109\/10641959709031638"},{"key":"2025122509325251000_327.7421.955.46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1447-0756.1996.tb00930.x","article-title":"Sublingual nifedipine compared with intravenous hydrallazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice.","volume":"22","author":"Jegasothy","year":"1996","journal-title":"J Obstet Gynaecol Res"},{"key":"2025122509325251000_327.7421.955.47","first-page":"328","article-title":"A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy.","volume":"70","author":"Mabie","year":"1987","journal-title":"Obstet Gynecol"},{"key":"2025122509325251000_327.7421.955.48","doi-asserted-by":"crossref","unstructured":"Martins-Costa S Ramos JG Barros E Bruno RM Costa CA Goldin JR . Randomized, controlled trial of hydralazine versus nifedipine in preeclamptic women with acute hypertension. Clin Exper Hypertens Pregn 1992;B11: 25\u00e2\u0080\u009344.","DOI":"10.3109\/10641959209031031"},{"key":"2025122509325251000_327.7421.955.49","first-page":"525","article-title":"Ketanserin and hydralazine in hypertension in pregnancy-a randomised double-blind trial.","volume":"85","author":"Rossouw","year":"1995","journal-title":"S Afr Med J"},{"key":"2025122509325251000_327.7421.955.50","first-page":"248","article-title":"Nifedipine in acute hypertensive emergencies in pregnancy.","volume":"76","author":"Seabe","year":"1989","journal-title":"S Afr Med J"},{"key":"2025122509325251000_327.7421.955.51","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00001703-199604000-00005","article-title":"Management of severe preeclampsia.","volume":"8","author":"Sibai","year":"1996","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2025122509325251000_327.7421.955.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08778-0"},{"key":"2025122509325251000_327.7421.955.53","doi-asserted-by":"crossref","unstructured":"Duley L Henderson-Smart DJ . Drugs for rapid treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2002;(4); CD001449","DOI":"10.1002\/14651858.CD001449"},{"key":"2025122509325251000_327.7421.955.54","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(99)70314-5"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.327.7421.955","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.327.7421.955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T17:33:01Z","timestamp":1766683981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.327.7421.955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,23]]},"references-count":54,"journal-issue":{"issue":"7421","published-online":{"date-parts":[[2003,10,23]]},"published-print":{"date-parts":[[2003,10,25]]}},"alternative-id":["10.1136\/bmj.327.7421.955"],"URL":"https:\/\/doi.org\/10.1136\/bmj.327.7421.955","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1468-5833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,23]]}}}